{
  "docId": "019de515-bf16-778d-9d2b-a6c6e17ebc6c",
  "docSlug": "7a45cce2c7eb1605e2a52f1d1ebe6b6d",
  "documentTitle": "MaxCyte | Investor Presentation Deck | 20 slides",
  "authorId": "maxcyte",
  "authorName": "MaxCyte",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 20,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "revenue_buildup",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de515-bf16-778d-9d2b-a6c6e17ebc6c/6",
  "deckHref": "/decks/019de515-bf16-778d-9d2b-a6c6e17ebc6c",
  "deckJsonHref": "/decks/019de515-bf16-778d-9d2b-a6c6e17ebc6c.json",
  "deckAnchorHref": "/decks/019de515-bf16-778d-9d2b-a6c6e17ebc6c#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.41,
        "x": 0.513,
        "y": 0.14
      },
      "kind": "chart",
      "text": "Cumulative Potential Pre-CML Milestones >$1.55B USD*",
      "attrs": {
        "chart_type": "line",
        "y_axis_label": ">$1.55B USD*",
        "x_axis_labels": [
          "2017",
          "2018",
          "2019",
          "2020",
          "2021",
          "2022",
          "2023"
        ]
      },
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c5e0e34-02d7-485d-8dd9-f9b788958a0e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.36,
        "x": 0.54,
        "y": 0.26
      },
      "kind": "image",
      "text": "KSQ, VOR, invios, editas, CARIBOU BIOSCIENCES, PRECISION BIOSCIENCES, Beam, Kite, CASEBIA, CRISPR, Allogene, celularity, MYELCID, INTIMA BIOSCIENCE, curamys, nkarta, Sana, VERTEX, LG Chem, WALKING FISH, catamaranBio",
      "attrs": {},
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "44a57d65-b862-4a20-ba33-616076b64e86",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.34,
        "x": 0.143,
        "y": 0.73
      },
      "kind": "list",
      "text": "Milestone revenue is MaxCyte's highest growth revenue stream",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d66f297-f947-4a1a-a159-e95901bb9487",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.34,
        "x": 0.143,
        "y": 0.59
      },
      "kind": "list",
      "text": "Recurring revenues from lease of instruments and sales of single-use disposables that grow with program success",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12edb553-e41e-4d14-99d1-2b01d346136a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.34,
        "x": 0.143,
        "y": 0.333
      },
      "kind": "list",
      "text": "Potential value of pre-commercial (clinical development) milestones from SPLs exceeds $1.55B USD*",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15008dec-22ec-4548-a4a7-6a3f536e6064",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.34,
        "x": 0.143,
        "y": 0.473
      },
      "kind": "list",
      "text": "Sales-based payments upon partner's product commercialization",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f8c6aa1-f23f-43a5-8015-9c353fc0c541",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.34,
        "x": 0.143,
        "y": 0.185
      },
      "kind": "paragraph",
      "text": "Licensing deals include significant development milestones and high-value participation in future commercial success of partners",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4227f6a1-a736-4f2f-9c2e-5c9736b5a3f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.01,
        "w": 0.18,
        "x": 0.606,
        "y": 0.845
      },
      "kind": "source-note",
      "text": "Graph is provided for illustrative purposes only.",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b604510-4305-4459-9098-1ee63cc5a8eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.01,
        "w": 0.09,
        "x": 0.826,
        "y": 0.845
      },
      "kind": "source-note",
      "text": "*As of December 2022",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "821b95d1-d051-47ee-8f81-10a55476885d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.399,
        "x": 0.079,
        "y": 0.839
      },
      "kind": "source-note",
      "text": "**Casebia/CRISPR's SPL partnership (signed in 2017) included the rights to use MaxCyte's technology in the development of exa-cel (formerly known as CTX001). As announced in the press release on September 28th, 2022, Vertex has signed an SPL agreement with MaxCyte - Vertex has obtained the clinical and commercial rights to use MaxCyte's technology for the development of exa-cel (formerly known as CTX001).",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f89de021-fc40-4448-882b-85902b2cce45",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}